Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Pharmacist in deadly U.S. meningitis outbreak resentenced to 10-1/2 years in prison

Published 07/21/2021, 11:33 AM
Updated 07/21/2021, 11:41 AM
© Reuters. FILE PHOTO: Glenn Adam Chin leaves the federal courthouse in Boston, Massachusetts September 11, 2014 following his arraignment on a mail fraud charge.     REUTERS/Brian Snyder

By Nate Raymond

BOSTON (Reuters) - An ex-pharmacist at a Massachusetts compounding pharmacy whose mold-tainted drugs sparked a deadly fungal meningitis outbreak in 2012 was resentenced on Wednesday to 10-1/2 years in prison after an appeals court tossed his earlier eight-year punishment.

Glenn Chin, the now-defunct New England Compounding Center's supervisory pharmacist, was sentenced for a second time by U.S. District Judge Richard Stearns in Boston two weeks after co-founder Barry Cadden received a new prison term of 14-1/2 years.

Both men were separately convicted in 2017 of racketeering and fraud over misrepresentations to NECC customers about its drugs but were cleared of second-degree murder charges related to 25 patients' deaths.

Prosecutors said those deaths stemmed from a fungal meningitis outbreak traced back to mold-tainted steroids that Framingham, Massachusetts-based NECC produced in filthy and unsafe conditions and sold to hospitals and clinics nationally.

The outbreak sickened 793 patients, more than 100 of whom died.

Prosecutors said Chin, while supervising the so-called clean rooms in which NECC's drugs were made, directed staff to ship untested drugs, use expired ingredients, falsify cleaning logs and ignore mold and bacteria.

Chin, speaking from a jail cell, said he never intended for the contamination but had allowed for "shortcuts I knew were wrong."

"I feel responsible for what happened because I made the drugs that made so many people terribly sick, including those who have died," he said.

Stearns originally sentenced Cadden, NECC's co-owner and president, and Chin to nine and eight years, respectively, prompting a successful appeal by prosecutors who considered the penalties too lenient. Prosecutors had initially sought 35-year prison terms for both men.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Stearns on Wednesday also ordered Chin to jointly with Cadden pay $82 million in restitution to their victims and forfeit $473,584 to the government.

Both men are now awaiting trial on separate second-degree murder charges in Michigan, which was hit hard by the outbreak.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.